© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Leukemias
Real-World MRD Responses Observed With NGS in Acute Lymphoblastic Leukemia and Other Lymphoid Cancers
May 27, 2020
"The ability for NGS to assess response across a continuum of relevant MRD threshold levels is an important consideration for applying MRD testing in clinical practice."
Analyzing CAR T-Cell Neurotoxicity in Adult Patients With ALL
May 18, 2020
Jae Park, MD, discusses adverse events associated with chimeric antigen receptor T-cell therapies, such as neurotoxicity, for patients with acute lymphocytic leukemia.
Microfluidic Platforms Help Isolate Rare Cells in Leukemias
May 17, 2020
In an interview with Targeted Oncology, Steve A. Soper, PhD, discussed microfluidic platforms for use in isolating circulating leukemia cells and plasma cells in patients with acute lymphoblastic leukemia and acute myeloid leukemia.
FDA Grants Orphan Drug Designation to HQP1351 in Chronic Myeloid Leukemia
May 04, 2020
There is a significant unmet clinical need [for] treatment of CML globally. This Orphan Drug Designation from FDA marks a major milestone for HQP1351..."
Longest Follow-Up Maintains Ibrutinib Benefit in CLL/SLL Across Treatment Settings
April 13, 2020
The longest follow-up for ibrutinib monotherapy to date maintained the benefit of the Bruton’s tyrosine kinase inhibitor for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma across settings.
Frontline Treatment Options Available for Patients With CLL
April 11, 2020
Jennifer Woyach, MD, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia.
Prognostic Tool Predicts Length of Watch and Wait Period in CLL
April 10, 2020
The appropriate gap between diagnosis of chronic lymphocytic leukemia and treatment is now clearer as a new prognostic tool, IPS-E, that can predict the length of “watch and wait” has been introduced, according to a press release from the American Society of Hematology.
Evaluating Older Patients With Acute Myeloid Leukemia in SIERRA Trial
April 08, 2020
Rajneesh Nath, MD, discusses the rationale for phase III SIERRA trial, which evaluated the anti-CD45 monoclonal antibody apamistamab followed by fludarabine/total body irradiation and allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia.
Early FCR Lacks Evidence to Change Standard Watch & Wait in Stage Binet A High-Risk CLL
April 02, 2020
Although fludarabine, cyclophosphamide, and rituximab may be efficient in inducing remission for the treatment of patients with Binet A high-risk chronic lymphocytic leukemia, recent data published in Leukemia suggest there is no evidence that this would be better than the current standard of care, which is the “watch and wait” approach.
Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia
April 02, 2020
Jeff P. Sharman, MD, discusses the secondary end points from the phase III ELEVATE-TN trial, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.